These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1077 related articles for article (PubMed ID: 12738903)

  • 1. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
    Ruiz Manzano J; Monreal M
    Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anticoagulation in patients with venous thromboembolism].
    Rüfer A; Wuillemin WA
    Ther Umsch; 2003 Jan; 60(1):43-7. PubMed ID: 12638478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparin in the treatment of pulmonary embolism.
    Ageno W; Turpie AG
    Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preventing venous thromboembolism].
    Encke A; Haas S
    Chirurg; 2007 Feb; 78(2):110, 112-8. PubMed ID: 17265054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients.
    Lee AY
    Curr Opin Pulm Med; 2003 Sep; 9(5):351-5. PubMed ID: 12904702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK; Dembitzer AD; Sanders GD; Garber AM
    Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
    Gould MK; Dembitzer AD; Doyle RL; Hastie TJ; Garber AM
    Ann Intern Med; 1999 May; 130(10):800-9. PubMed ID: 10366369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
    Falciani M; Dilaghi B; Conti AA; Caciolli S; Gensini GF
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):27-35. PubMed ID: 11253337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of venous thromboembolism in polytraumatized patients. Epidemiology and importance].
    Venet C; Berger C; Tardy B; Viallon A; Decousus H; Bertrand JC
    Presse Med; 2000 Jan; 29(2):68-75. PubMed ID: 10682030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins].
    Delsart D; Chambefort V; Decousus H
    Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082
    [No Abstract]   [Full Text] [Related]  

  • 19. Tinzaparin in the treatment of venous thromboembolism.
    Pineo GF; Hull RD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of unfractionated heparin for thromboembolism prophylaxis in medical patients.
    Yalamanchili K; Sukhija R; Sinha N; Aronow WS; Maguire GP; Lehrman SG
    Am J Ther; 2005; 12(4):293-9. PubMed ID: 16041191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.